News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Study Shows Sequenta, Inc.’s Sequencing-Based Minimal Residual Disease (MRD) Detection Technology Has Prognostic Value In Multiple Myeloma


5/15/2014 8:41:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sequenta, Inc. today announced publication of a study demonstrating that the company’s ultra-sensitive sequencing-based minimal residual disease (MRD) detection technology, available clinically as the ClonoSIGHT™ test, provides important prognostic information in multiple myeloma. Both time to progression (TTP) and overall survival (OS) were shown to be significantly longer in MRD-negative patients compared those who were MRD-positive (n=110; median TTP: 80 months vs. 31 months, p<0.0001; median OS: not reached vs. 81 months, p=0.02).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES